<a href="https://www.fiercebiotech.com/biotech/sanofi-halts-phase-3-autoimmune-trial-early-over-lackluster-efficacy" hreflang="en">Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue</a>
Sanofi has prematurely halted a phase 3 clinical trial for its autoimmune therapy riliprubart due to insufficient efficacy, marking another setback for the company amidst ongoing pipeline challenges. This decision follows a series of recent clinical failures and could potentially benefit competitors in the immunoglobulin market.
Sanofi's decision to halt its phase 3 trial for the autoimmune drug riliprubart due to insufficient efficacy underscores the critical importance of robust mid-phase data for pipeline viability in drug development. For professionals tracking healthtech and biotech, this development highlights a potential opportunity for competing companies like Argenx and Dianthus Therapeutics with their alternative CIDP treatments, as success in their ongoing trials could capture market share vacated by Sanofi's setback. This situation also serves as a cautionary tale about the risks of prematurely advancing compounds with unproven efficacy in high-stakes late-stage trials.